随着冠状病毒根据美国广播公司新闻获得的一份新的联邦情报报告，疫情继续在世界各地蔓延，美国“很可能”会出现仿制药短缺。
这份报告由国土安全部编写，周四分发给全国各地的执法机构和政府机构。报告警告称，由于流感大流行早期的国际关闭造成供应链紧张，美国已经出现了200多种药品和医疗用品的短缺。
分析师们总结称，如果不加控制的疫情爆发迫使又一轮大范围关闭，这种短缺只会变得更糟，从而进一步加大系统的压力，以至于许多美国制药公司将“无法迅速弥补”
报道援引新闻报道称:“生产普通抗生素原料的中国工厂自3月起关闭数周，印度的封锁期延长至5月底。”。"随着COVID-19案件开始重新出现，法国、德国和中国也考虑重新实施封锁措施."
这一警告来自一些州的官员已经停止了一些重新开放的计划或者关闭为冠状病毒根据美国广播公司新闻分析，病例在至少29个州上升。佛罗里达周五报告了将近9000个新病例，这是自大流行开始以来的最高数字。
在这张2018年6月15日的照片中，药品出现在马萨诸塞州的北安多弗。
全国最高传染病官员安东尼·福西博士做了什么他向全国发出了“恳求”周五，了解疫情，主要是在南部和西部，可能会蔓延到整个国家。
“如果我们不扑灭疫情，早晚会发生的，即使是那些做得好的，也很容易受到传播的影响，”福西说。“因此，我们需要考虑到这一点，因为我们都在其中，而我们结束这一局面的唯一方式就是一起结束它。”
然而，副总统迈克·彭斯表示，该国在前进道路上取得了“真正显著的进步”，并称赞“该国所有50个州都在安全和负责任地开放”，然后承认有所增加。
美国医院协会前医学主管杰伊·巴特博士称这份报告“非常令人担忧”，尤其是在大流行期间。
美国广播公司新闻撰稿人巴特说:“弱势人群获得负担得起的仿制药可能意味着好结果和坏结果的区别。”。“随着感染和住院人数的增加，我们的病人无法忍受救命药物的短缺。我们必须吸取几个月前的教训，这样我们才不会陷入困境。”
2017年6月9日，在印度西部果阿省武诗源，一名员工在印度第二大制药商卢平的一家制药厂的生产线上检查药片。
该报告进一步警告说，药品短缺将对低收入美国人产生不成比例的影响。
该报告发现，仿制药的价格明显低于名牌仿制药，如果仿制药价格下降，将“对低收入和失业的美国人的健康构成最大威胁”，因为他们已经受到了大流行的经济困难的沉重打击。
“买不起仿制药的人不太可能转而使用名牌处方，因为它们的价格可能会高出95%，”该报告援引美国一家制药研究公司和美国食品药品管理局一项研究的数据称。
巴特说:“我担心服务不足的社区和安全网医院在城市和农村社区也没有大量资源。”。“我希望医院和没有面临短缺的州能够与那些满足需求的州分享。”
US 'likely' to see shortage of pharmaceutical drugs if coronavirus outbreak continues, intelligence report finds
Withcoronavirusoutbreaks continuing to spread across the world, the United States is "likely" to see a shortage of generic pharmaceutical drugs, according to a new federal intelligence report obtained by ABC News.
The report, prepared by the Department of Homeland Security and distributed Thursday to law enforcement and government agencies around the country, warned that the U.S. is already seeing shortages of more than 200 drugs and medical supplies due to strains on the supply chain caused by international shutdowns early on in the pandemic.
Those shortages would only be made worse should unchecked outbreaks force yet another round of widespread shutdowns, the analysts concluded, further straining the system in a way that many U.S.-based pharmaceutical companies would be "unable to quickly offset."
"Chinese factories that produce raw ingredients for common antibiotics closed for weeks as of March and India's lockdown extended until the end of May," the report said, citing news reports. "France, Germany, and China have also considered re-imposing lockdown measures as COVID-19 cases have begun to re-emerge."
The warning comes as officials in some states havealready halted some reopening plansor closed back down ascoronaviruscases rise in at least 29 states, according to an ABC News analysis. Florida reported just under 9,000 new cases on Friday, the highest number since the start of the pandemic.
In this June 15, 2018 photo, pharmaceuticals are seen in North Andover, Mass.
Dr. Anthony Fauci, the nation's top infectious disease official, made whathe called a "plea" to the countryon Friday to understand that the outbreaks, which are mainly in the South and West, could potentially spread to the entire country.
"If we don't extinguish the outbreak, sooner or later, even ones that are doing well are going to be vulnerable to the spread," Fauci said. "So we need to take that into account because we are all in it together, and the only way we're going to end it is by ending it together."
Vice President Mike Pence, however, said the country has made "truly remarkable progress" in moving forward and commended "all 50 states in this country are opening up safely and responsibly" before acknowledging some increases.
Dr. Jay Bhatt, former medical chief at the American Hospital Association, called the report "extremely concerning" -- especially in the middle of a pandemic.
"Accessing affordable generic medications for vulnerable populations can mean the difference between a good outcome and a bad outcome," said Bhatt, an ABC News contributor. "As infections and hospitalizations rise, our patients can't endure shortages from lifesaving medications. We have to apply our lessons from several months ago so we don't end up in dire straits."
An employee inspects tablets as they move along the production line at a pharmaceutical plant of Lupin, India's No. 2 drugmaker, in Verna, in the western state of Goa, India, June 9, 2017.
The report further warned drug shortages would have a disproportionate effect on low-income Americans.
A decrease in generic pharmaceuticals, which are significantly less expensive than their brand-name counterparts, would "most risk the health of low-income and unemployed Americans," who have already been hard hit by the economic hardships of the pandemic, the report found.
"Individuals who cannot afford generic pharmaceuticals are unlikely to switch to brand-name prescriptions because they can cost as much as 95 percent more," the report said, citing data from a U.S. pharmaceutical research company and a Food and Drug Administration study.
"I am worried about underserved communities and safety net hospitals without significant resources in urban and rural communities as well," Bhatt said. "I hope hospitals and states not facing shortages can share with those that are to meet the need."
